IDYA
IDEAYA Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.7% ·
share flow -10.4% ·
net new positions -8.3%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | +5 | 68.11M | $2.53B | +11 | −5 |
| Q1 2026 | 98 | +2 | 72.39M | $2.41B | +9 | −8 |
| Q4 2025 | 96 | 0 | 74.31M | $2.57B | +1 | n/a |
| Q3 2025 | 17 | -1 | 45.06M | $1.23B | n/a | −2 |
| Q2 2025 | 16 | 0 | 43.75M | $919.60M | +1 | −1 |
| Q1 2025 | 13 | -1 | 14.55M | $238.33M | +1 | −2 |
| Q4 2024 | 14 | +1 | 14.99M | $385.22M | +1 | n/a |
| Q3 2024 | 12 | -1 | 10.73M | $339.97M | n/a | −1 |
| Q2 2024 | 13 | n/a | 11.98M | $420.72M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 4.02M | +7.2% | $127.21M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 1.95M | +9.8% | $61.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 1.05M | -28.9% | $33.34M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 980.09K | -52.5% | $31.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Fisher Asset Management ✦ | 848.91K | +26.7% | $26.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 567.73K | -35.8% | $17.99M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 498.59K | -17.5% | $15.80M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 342.08K | +32.3% | $10.84M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Marshall Wace ✦ | 252.31K | +155.3% | $7.99M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 170.37K | +55.8% | $5.40M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 42.11K | -77.6% | $1.33M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 12 | AQR Capital Management ✦ | 15.75K | +0.8% | $499,023 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $3.25M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 253 holders, 94.40M shares, $3.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 25.54K sh · $954,787
Officer, Director · 800 sh · $30,610
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology